Company profile: CandidRx
1.1 - Company Overview
Company description
- Provider of T-cell engager and bispecific antibody therapeutics for autoimmune diseases, developing candidates that redirect T cells to eliminate autoreactive B cells for deeper depletion. Pipeline includes CND106 (BCMAxCD3), a bispecific targeting BCMA and CD3 to remove autoantibody-producing B cells, and CND261 (CD20xCD3), a bispecific targeting CD20 and CD3 to address a broad range of B-cell subtypes.
Products and services
- CND106 (BCMAxCD3) Antibody: A bispecific antibody targeting BCMA and CD3 that redirects T-cells to eliminate autoantibody-producing B-cells in autoimmune diseases, achieving deeper B-cell depletion
- CND261 (CD20xCD3) Antibody: A bispecific antibody engaging CD20 and CD3 to redirect T-cells and deplete a broad range of B-cell subtypes, enhancing efficacy in autoimmune disease treatment
- T-cell Engager Antibodies: Antibody-based components that redirect T-cells to eliminate autoreactive B-cells, aiming for effective autoimmune disease treatment by achieving deeper B-cell depletion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CandidRx
Epiva
HQ: United States
Website
- Description: Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiva company profile →
One Lambda
HQ: United States
Website
- Description: Provider of histocompatibility (HLA) typing tests using serological and molecular technologies, and manufacturer of antibody detection products, laboratory instrumentation, and computer software used to simplify and automate testing procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full One Lambda company profile →
BioXell
HQ: Italy
Website
- Description: Provider of recombinant protein expression and purification services; stable cell line generation using proprietary ExoIN technology and cGMP-compliant CHO-based platforms; transient protein expression; customized protein expression screening; high-yield recombinant protein production in E. coli, yeast, and mammalian systems; and monoclonal and polyclonal antibody development via hybridoma and phage display.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXell company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
Noveome Biotherapeutics
HQ: United States
Website
- Description: Provider of regenerative repair therapies for inflamed or damaged tissues via ST266, a multi-targeted secretome of biologically active proteins for neuroprotection, inflammation modulation, cell recovery, and healing in ophthalmology, neurology, and dermatology; explored in PEDs, optic neuritis, glaucoma (Phase I), NEC, and COVID-19/sepsis cytokine storm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noveome Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CandidRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CandidRx
2.2 - Growth funds investing in similar companies to CandidRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CandidRx
4.2 - Public trading comparable groups for CandidRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →